共 50 条
Protection against leptospirosis conferred by Mycobacterium bovis BCG expressing antigens from Leptospira interrogans
被引:9
|作者:
Dorneles, Jessica
[1
]
Madruga, Andriele Bonemann
[1
]
Pinto Seixas Neto, Amilton Clair
[1
]
Rizzi, Caroline
[1
]
Bettin, Everton Burlamarque
[1
]
Hecktheuer, Amanda Silva
[1
]
de Castro, Clarissa Caetano
[2
]
Fernandes, Cristina Gevehr
[2
]
Oliveira, Thais Larre
[1
]
Dellagostin, Odir Antonio
[1
]
机构:
[1] Univ Fed Pelotas, Ctr Desenvolvimento Tecnol, Programa Posgrad Biotecnol, Pelotas, RS, Brazil
[2] Univ Fed Pelotas, Dept Patol Anim, Programa Posgrad Vet, Pelotas, RS, Brazil
来源:
关键词:
Vectored vaccine;
BioBricks;
Chimera;
LipL32;
LigAni;
LemA;
VACCINE;
D O I:
10.1016/j.vaccine.2020.10.086
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Leptospirosis is a zoonotic disease worldwide and caused by the pathogenic spirochetes of the genus Leptospira. Bacterins make up the vaccines used against leptospirosis, but they only succeed in providing short-term and serovar-specific protection. The use of Mycobacterium bovis BCG as a live vaccine vector expressing leptospiral antigens is a promising alternative, particularly due to its adjuvant properties. Four distinct portions P-1 (lipL32), P-2 (ligAni), P3 (lemA: ligAni) and P-4 (lipL32:lemA) of a recombinant chimera composed of the lipL32, lemA and ligANI genes from Leptospira interrogans were cloned individually according to the BioBricks (R) strategy in the plasmid pUP500/PpAN. These constructs were individually transformed into a BCG Pasteur strain, and protein expression was detected by Western blot. For vaccination, 5 groups of 10 Golden Syrian hamsters were used, aged 4-6 weeks - group 1, rBCG (LipL32); group 2, rBCG (LigAni); group 3, rBCG (LemA:LigAni); group 4, (LipL32:LemA); group 5, wild-type BCG Pasteur (negative control). Two doses containing 10(6) CFU of rBCG were administered subcutaneously, the challenge was performed with 5 x LD50 of Leptospira interrogans serovar Copenhageni L1-130, and the animals were observed for a 30-day period until the endpoint was reached. Humoral immunity was assessed via indirect ELISA, while renal colonisation was assessed by culture and quantitative real-time PCR. All vaccinated groups were protected against lethal challenge and renal colonisation, in comparison with negative control group (P < 0.05). Recombinant vaccines were not effective at inducing significant humoral immunity, which suggests the induction of cellular immunity - a characteristic of M. bovis BCG. In conclusion, all formulations provide 100% significant protection against leptospirosis in hamsters with no renal colonisation. The use of rBCG as a vaccine vector represents a promising alternative for the control of animal leptospirosis, allowing for protection against clinical signs of leptospirosis and renal colonisation. (C) 2020 Elsevier Ltd. All rights reserved.
引用
收藏
页码:8136 / 8144
页数:9
相关论文